Clinical Trial Update: Probiotic Visbiome for Inflammation and Translocation in HIV Ι [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Visbiome, a probiotic, for inflammation and translocation in HIV infection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Visbiome

Snippet

Sponsor: University Health Network, Toronto | Conditions: HIV-1 Infection | Phase 2 | Status: TERMINATED